About Annexon Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://annexonbio.com/
Frequently Asked Questions
What is the 52-week range for ANNX?
The 52-week high is $7.18 and the 52-week low is $2.54.
What is the P/E ratio for ANNX?
The P/E ratio data is currently unavailable.
What is the dividend yield for ANNX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -106.15%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.43.
Analyst Recommendation Trends
Wall Street analyst consensus for ANNX over the last few months:
Latest ANNX News
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for more on ANNX stock.
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immuno
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule
Annexon, Inc. (ANNX) Virtual Business Update Call Transcript
Annexon (ANNX) Virtual Business Update Call recap: Phase III updates for GBS and geographic atrophy, r
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Love Douglas | +26,065 | $3.83 | $99,829 |
| 2026-08-10 | Blumenkranz Mark S. | +175,000 | - | - |
| 2026-06-11 | Cockroft Bettina M. | +65,000 | - | - |
| 2026-06-11 | Carson William H. | +65,000 | - | - |
| 2026-06-11 | Yednock Ted | -30,646 | - | - |
| 2026-06-11 | Yednock Ted | +30,646 | $1.8501 | $56,698 |
| 2026-06-11 | Choi Jung | +65,000 | - | - |
| 2026-06-11 | Waddill William D. | +65,000 | - | - |
| 2026-06-11 | JONES WILLIAM A JR | +65,000 | - | - |
| 2026-06-11 | Satter Muneer A | +65,000 | - | - |
| 2026-05-28 | Satter Muneer A | +613,497 | $5.41 | $3,319,019 |
| 2026-05-11 | Carson William H. | +8,000 | $5.78 | $46,240 |
| 2026-04-10 | Carson William H. | +8,000 | $6.2 | $49,600 |
| 2026-03-10 | Carson William H. | +8,000 | $5.67 | $45,360 |
| 2026-03-02 | ARTIS DEAN RICHARD | -5,894 | $5.43 | $32,004 |
| 2026-03-02 | Yednock Ted | -5,566 | $5.42 | $30,168 |
| 2026-03-02 | Overdorf Michael | -4,339 | $5.42 | $23,517 |
| 2026-03-02 | Dananberg Jamie | -5,820 | $5.43 | $31,603 |
| 2026-03-02 | Lew Jennifer | -5,565 | $5.42 | $30,162 |
| 2026-02-19 | ARTIS DEAN RICHARD | +250,000 | - | - |
| 2026-02-19 | ARTIS DEAN RICHARD | +62,500 | - | - |
| 2026-02-19 | Yednock Ted | +250,000 | - | - |
| 2026-02-19 | Yednock Ted | +62,500 | - | - |
| 2026-02-19 | Overdorf Michael | +250,000 | - | - |
| 2026-02-19 | Overdorf Michael | +62,500 | - | - |
| 2026-02-19 | Love Douglas | +1,250,000 | - | - |
| 2026-02-19 | Dananberg Jamie | +225,000 | - | - |
| 2026-02-19 | Dananberg Jamie | +56,250 | - | - |
| 2026-02-19 | Lew Jennifer | +250,000 | - | - |
| 2026-02-19 | Lew Jennifer | +62,500 | - | - |
| 2026-02-18 | ARTIS DEAN RICHARD | -5,290 | $5.1 | $26,979 |
| 2026-02-18 | Yednock Ted | -7,857 | $5.11 | $40,149 |
| 2026-02-18 | Overdorf Michael | -6,225 | $5.1 | $31,747 |
| 2026-02-18 | Dananberg Jamie | -5,290 | $5.1 | $26,979 |
| 2026-02-18 | Lew Jennifer | -7,851 | $5.11 | $40,119 |
| 2025-12-30 | Carson William H. | +4,115 | $5.02 | $20,657 |
| 2025-12-01 | Carson William H. | +4,115 | $4.47 | $18,394 |
| 2025-12-01 | Choi Jung | +33,000 | $4.19 | $138,270 |
| 2025-11-21 | Satter Muneer A | +422,613 | $4.28 | $1,808,784 |
| 2025-11-20 | Satter Muneer A | +400,000 | $4.48 | $1,792,000 |
| 2025-11-19 | Satter Muneer A | +500,000 | $3.94 | $1,970,000 |
| 2025-11-18 | Satter Muneer A | +500,000 | $3.18 | $1,590,000 |
| 2025-11-17 | Satter Muneer A | +500,000 | $2.99 | $1,495,000 |
| 2025-10-30 | Carson William H. | +4,115 | $3.17 | $13,045 |